Evidence map›Paper›PMID 26806567›Full record

ArticleThe Journal of pathology2016

Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Elena Guerini-Rocco, Salvatore Piscuoglio, Charlotte K Y Ng, Felipe C Geyer, Maria R De Filippo, Carey A Eberle, Muzaffar Akram, Nicola Fusco, Shu Ichihara, Rita A Sakr and 8 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The Journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Pathogenesis of Triple-Negative Breast Cancer.Annual review of pathology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Reply to Rosen.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 6 countries.

Elena Guerini-RoccoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Salvatore PiscuoglioDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charlotte K Y NgDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Felipe C GeyerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria R De FilippoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carey A EberleDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Muzaffar AkramDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicola FuscoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shu IchiharaDepartment of Pathology, Nagoya Medical Center, Nagoya, Japan.
Rita A SakrDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yasushi YatabeDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Anne Vincent-SalomonDepartment of Biopathology, Institut Curie, Paris, France.
Emad A RakhaDepartment of Pathology, Nottingham University, Nottingham, UK.
Ian O EllisDepartment of Pathology, Nottingham University, Nottingham, UK.
Y Hannah WenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stuart J SchnittDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USUniversity of Nottingham · GBAichi Cancer Center · JPEuropean Institute of Oncology · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHarvard University · USInstitut Curie · FRNagoya Medical Center · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748
6 · The paper itself

Abstract

Microglandular adenosis (MGA) is a rare proliferative lesion of the breast composed of small glands lacking myoepithelial cells and lined by S100-positive, oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative epithelial cells. There is evidence to suggest that MGA may constitute a non-obligate precursor of triple-negative breast cancer (TNBC). We sought to define the genomic landscape of pure MGA and of MGA, atypical MGA (AMGA) and associated TNBCs, and to determine whether synchronous MGA, AMGA, and TNBCs would be clonally related. Two pure MGAs and eight cases of MGA and/or AMGA associated with in situ or invasive TNBC were collected, microdissected, and subjected to massively parallel sequencing targeting all coding regions of 236 genes recurrently mutated in breast cancer or related to DNA repair. Pure MGAs lacked clonal non-synonymous somatic mutations and displayed limited copy number alterations (CNAs); conversely, all MGAs (n = 7) and AMGAs (n = 3) associated with TNBC harboured at least one somatic non-synonymous mutation (range 3-14 and 1-10, respectively). In all cases where TNBCs were analyzed, identical TP53 mutations and similar patterns of gene CNAs were found in the MGA and/or AMGA and in the associated TNBC. In the MGA/AMGA associated with TNBC lacking TP53 mutations, somatic mutations affecting PI3K pathway-related genes (eg PTEN, PIK3CA, and INPP4B) and tyrosine kinase receptor signalling-related genes (eg ERBB3 and FGFR2) were identified. At diagnosis, MGAs associated with TNBC were found to display subclonal populations, and clonal shifts in the progression from MGA to AMGA and/or to TNBC were observed. Our results demonstrate the heterogeneity of MGAs, and that MGAs associated with TNBC, but not necessarily pure MGAs, are genetically advanced, clonal, and neoplastic lesions harbouring recurrent mutations in TP53 and/or other cancer genes, supporting the notion that a subset of MGAs and AMGAs may constitute non-obligate precursors of TNBCs.

Indexed as

MutationAgedBiomarkers, TumorCarcinomaCarcinoma in SituDisease ProgressionDNA Mutational AnalysisFemaleFibrocystic Breast DiseaseGenetic Predisposition to DiseaseHumansImmunohistochemistryMiddle AgedPhenotypePrecancerous ConditionsRetrospective StudiesBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53breast cancer precursormutationstargeted capture massively parallel sequencingTP53triple-negative breast cancer

Identifiers

PMID26806567
PMCPMC4962789
OpenAlexW2256857720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.